Tumour necrosis factor inhibitors: maximizing patient safety
نویسندگان
چکیده
منابع مشابه
Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated of...
متن کاملSafety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
OBJECTIVES There is no consensus on whether restarting TNF inhibitors (TNFis) after treatment of an active tuberculosis (TB) infection caused by previous TNFi exposure is safe. In this study we sought to determine the safety of resuming TNFis in patients following TB treatment. METHODS The medical records of all patients (n = 683) that received TNFi treatment at a single rheumatology clinic b...
متن کاملSignal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.
Many biological functions are regulated through interactions of extracellular molecules with their cognate cell surface receptors. The transduction of these signals by their receptors at the plasma membrane to the intracellular machinery results in such cellular activities as gene activation, protein phosphorylation, cell proliferation, and cell destruction. Though the kinetics of these activit...
متن کاملLong-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis.
OBJECTIVES To assess the long-term safety and effectiveness of tumour necrosis factor (TNF) inhibitors in the treatment of systemic sclerosis (SSc) patients with inflammatory arthritis. METHODS SSc patients who fulfilled the ACR criteria and had inflammatory arthritis followed in The Scleroderma Programme at the Mount Sinai and Toronto Western Hospitals, Toronto, Canada who received a TNF inh...
متن کاملSarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors
OBJECTIVE To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitors (TNF-IR). METHODS 546 patients (81...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2003
ISSN: 1460-2172
DOI: 10.1093/rheumatology/keg046